Mesoblast Limited announced the FDA approved Ryoncil (remestemcel-L) as the first mesenchymal stromal cell (MSC) therapy in the United States. Rynocil is the only MSC therapy approved in… read more.
Incyte has announced that the FDA has approved Jakafi (ruxolitinib) for treatment of chronic graft-versus-host disease (GVHD) after failure of one or two lines of systemic therapy in… read more.
Incyte announced that positive data from the Phase III REACH3 study have been published in The New England Journal of Medicine (NEJM) demonstrating that treatment with ruxolitinib (Jakafi)… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
